Mechanisms of Yiai Fuzheng formula in the treatment of triple-negative breast cancer based on UPLC-Q-Orbitrap-HRMS, network pharmacology, and experimental validation
YAFZF therapy showed its potential for reducing proliferation, invasion, and migration abilities, increasing apoptosis of TNBC cells. Furthermore, YAFZF treated TNBC by inhibiting xenograft tumour distant metastases via the regulation of EMT by the PI3K/Akt/mTOR pathway, suggesting that it may be useful as an adjuvant treatment.
Authors
- Longzhu Ke
- Haoliang Ke
- Yingwen Zhang (ORCID: https://orcid.org/0000-0002-7777-3234)
- Pan Liu (ORCID: https://orcid.org/0000-0003-0559-6432)
- Qian Yang (ORCID: https://orcid.org/0000-0001-8778-4132)
- Yuxin Li (ORCID: https://orcid.org/0000-0001-7404-6595)
- Xiuping Wang (ORCID: https://orcid.org/0000-0003-0888-7120)
- Chaoyan Wu
- Ruijie Li (ORCID: https://orcid.org/0000-0001-7597-1619)
Institutions
- Hubei University of Chinese Medicine (CN)
- Wuhan University (CN)
- Zhongnan Hospital of Wuhan University (CN)
Publication Details
- Journal
- Heliyon
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e36579
- Citations
- 3
- Primary Topic
- Traditional Chinese Medicine Analysis
- Type
- article
- Field-Weighted Citation Impact
- 2.15